-
ScienceDaily
Jul 22, 2016, 9:22 pm52 ptsResearchers found that treating metastatic thyroid cancer patients harboring a BRAF mutation with the targeted therapy vemurafenib -- originally approved for melanoma patients with the mutation -- showed promising anti-tumor activity in a third of patients.
Trending Today on EcoTopical
Welcome to EcoTopical Your daily eco-friendly green news aggregator.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.